Lindsay Fischer

A final analysis of the phase 3 ClarIDHy trial revealed that OS was superior in patients receiving ivosidenib, despite a high crossover rate from the placebo group.

Kristin Rupp, RN, OCN, BSN, reminiscences about the experiences that made her the nurse she is today, and how she continues to pay it forward.

Parsaclisib has been granted a priority review for 3 indications that include relapsed or refractory follicular, marginal zone, and mantle cell lymphoma.

“It is not a ‘one and done kind of thing.” It is very important to implement these skills throughout the community. It's a practice. It's a behavioral change.”

The FDA have granted an accelerated approval to acimibinib, which treats CML by binding to the ABL myristoyl pocket.

The implementation of the Oncology Nursing Society’s new Get Up, Get Moving Program helped patients increase their daily step intake and maintain their health-related quality of life.

Health care professionals who treated patients throughout the COVID-19 pandemic and received CBD therapy reported less burnout and emotional exhaustion than those solely receiving standard-of-care treatment.

A recent study identified some of the key challenges in coordinated care for underinsured and uninsured cancer survivors who have initiated the surveillance stage of their journey.

A speaker at the Oncology Nursing Society Bridge Program discussed how nurses can build their own resilience and proactively protect their mental well-being.

Atezolizumab is the first immunotherapy approved in the adjuvant setting to treat NSCLC.

“Previously, this mutation has been undruggable, but this is now changing.”

An expert on immune toxicity management discusses dermatologic, gastrointestinal, hepatic, and endocrine irAEs and how nurses can help educate their patients to monitor these symptoms.

The Oncology Nurse Practitioner Fellowship at Sylvester Comprehensive Cancer Center exposes fellows to the gamut of oncology care and teaches the skills they need to succeed.

Pembrolizumab is approved both in combination with chemotherapy, with or without bevacizumab, and as a single agent for the treatment of patients with recurrent or metastatic cervical cancer.

Abemaciclib is the first and only FDA approved CDK4/6 inhibitor to treat HR-positive, HER2-negative high-risk early breast cancer.

An expert on pain management discusses safe and effective opioid prescriptions to manage cancer-related pain.

Deidra Hamilton, MSN, RN, OCN, ONN-CG, recently presented on how cancer institutions can clearly define the role of a nurse navigator to prevent scope creep and use gap analysis and metrics to showcase the value of a navigator in their program.

Kristin Barber, FNP-BC, AOCNP, discusses ongoing phase 1 trials aimed at targeting mutations along the MAP kinase pathway.

A new retrospective cohort found that women who had received the human papillomavirus vaccine had similar rates of primary ovarian insufficiency as unvaccinated women.

Loop electrical excision procedure (LEEP) demonstrated superior capabilities in clearing high-risk HPV infections in women with cervical intraepithelial neoplasia (CIN2+).

“When you’re donning that gown to go into a room, you’re donning exactly what that patient needs you to be.”

A recent study demonstrated that patients with prostate cancer on active surveillance reported reduced PSA levels after a 12-week HIIT regime.

Cetuximab represents the first approved anti-EGFR antibody which, in combination with encorafenib, is now available to treat adults with pretreated metastatic CRC with a BRAF V600E mutation.

The FDA has granted cemiplimab-rwlc a priority review based on findings from the largest to-date, randomized clinical trial in advanced cervical cancer.

An expert weighs in on the advantages of cannabis treatment for patients with cancer, and how nurses can help patients navigate the cannabis-oncology space, in spite of certain research limitations.

Sandra Duncan, RN, BSN, discusses her transition to clinical research, and what her responsibilities are like supporting the ongoing CheckMate-73L trial.

The FDA has approved ruxolitinib to treat adults with steroid-refractory chronic graft-versus-host disease.

Patients with nonmetastatic castration-resistant prostate cancer often undergo prolonged treatment periods, making the safety profile of therapies like darolutamide an important factor in optimum treatment selection.

The FDA has green lit mobocertinib for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with an EGFR exon 20 insertion mutation.

Zanubrutinib received an accelerated approval for the indication of adults with marginal zone lymphoma with at least 1 prior treatment with an anti-CD20-based therapy.